Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk received new equity awards. On May 27, 2026, Norwalk was granted 2,624 non-qualified stock options for common stock with an exercise price of $155.83 per share, expiring on May 27, 2036. These options vest in 12 monthly installments beginning on June 27, 2026.
Norwalk was also granted 1,284 Restricted Stock Units (RSUs), each representing the right to receive one share of common stock upon vesting. The RSUs will vest in full on May 27, 2027. These awards are compensation-related grants rather than open-market purchases or sales.
NEUROCRINE BIOSCIENCES INC Chief Corp. Affairs Officer David W. Boyer reported an open-market sale of 3,888 shares of common stock. The shares were sold at a weighted average price of $156.6418 per share in multiple trades between $155.81 and $157.62.
The transaction was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which the company’s policy does not allow him to amend after adoption. Following this sale, Boyer directly holds 7,799 shares, including 106 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
Neurocrine Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 27, 2026. Stockholders elected three Class III directors for terms expiring at the 2029 Annual Meeting and confirmed the existing Class I and Class II board structure.
Of 100,581,991 shares entitled to vote as of March 31, 2026, 90,118,625 were represented in person or by proxy. Stockholders approved on an advisory basis the compensation of named executive officers, and they approved the Amended 2025 Equity Incentive Plan as described in the company’s definitive proxy statement.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, confirming the company’s current external audit relationship.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing the proposed sale of 3,888 shares of Common Stock, with an indicated value of $609,249.60. The filing lists 01/31/2026 as the award date for the securities (Restricted Stock Awards / Performance Stock Units) and 05/26/2026 as the filing date. The securities are listed on NASDAQ.
NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. Following this compensation-related exercise, Sherwin directly holds 15,860 shares of Neurocrine common stock. The RSU award was granted on May 21, 2025 and is now fully vested, with no remaining units from this grant.
NEUROCRINE BIOSCIENCES INC director Shalini Sharp exercised restricted stock units into common stock. She acquired 1,659 shares of common stock from vested RSUs and did not sell any shares in this filing. Following the transaction, she directly holds 4,088 shares of common stock.
NEUROCRINE BIOSCIENCES INC director William H. Rastetter exercised restricted stock units into common shares. On May 21, 2026, he converted 3,318 Restricted Stock Units into 3,318 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related vesting event rather than a market purchase or sale.
After this transaction, Rastetter’s direct holdings increased to 43,678 common shares, which are held by the Rastetter Family Trust, where he has voting and investment power. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, and no remaining derivative position is reported in this filing.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. These RSUs were granted on May 21, 2025 and were fully vested. Following the transaction, Pops directly holds 37,798 shares of Neurocrine Biosciences common stock, reflecting a routine equity compensation event with no open-market buying or selling.